Latest News

Dr. Reddy’s Laboratories Announces the Launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market





HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA). The Renvela brand and generic had U.S. sales of approxima

Source link




Related posts

New study explains why heart failure patients have trouble with thinking and depression

Newsemia

Aggressive treatment for some stage IV lung cancer pts can dramatically improve OS

Newsemia

Incidence of stroke has risen steadily among marijuana users, show studies

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy